Cited by 518Lung Cancer Treatments and MutationsBrain Metastases and TreatmentLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)

Wu, Yi-Long, Ahn, Myung-Ju, Garassino, Marina Chiara, Han, Ji-Youn, Katakami, Nobuyuki, Kim, Hye Ryun, Hodge, Rachel, Kaur, Paramjit, Brown, Andrew P., Ghiorghiu, Dana, Papadimitrakopoulou, Vassiliki A., Mok, Tony S.K.·2018·Journal of Clinical Oncology

DOI 10.1200/jco.2018.77.9363

Open this paper in CoChat — free account

Abstract

Purpose In patients with epidermal growth factor receptor ( EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC), there is an unmet need for EGFR-tyrosine kinase inhibitors with improved CNS penetration and activity against CNS metastases, either at initial diagnosis or time of progression. We report the first comparative evidence of osimertinib CNS efficacy versus platinum-pemetrexed from a phase III study (AURA3; ClinicalTrials.gov identifier: NCT02151981) in patients with EGFR T790M-positive advanced NSCLC who experience disease progression with prior EGFR-tyrosine kinase inhibitor treatment. Methods Patients with asymptomatic, stable CNS metastases were eligible for enrollment and were randomly assigned 2:1 to osimertinib 80 mg once daily or platinum-pemetrexed. A preplanned subgroup analysis was conducted in patients with measurable and/or nonmeasurable CNS lesions on baseline brain scan by blinded independent central neuroradiological review. The CNS evaluable for response set included only patients with one or more measurable CNS lesions. The primary objective for this analysis was CNS objective response rate (ORR). Results Of 419 patients randomly assigned to treatment, 116 had measurable and/or nonmeasurable CNS lesions, including 46 patients with measurable CNS lesions. At data cutoff (April 15, 2016), CNS ORR in patients with one or more measurable CNS lesions was 70% (21 of 30; 95% CI, 51% to 85%) with osimertinib and 31% (5 of 16; 95% CI, 11% to 59%) with platinum-pemetrexed (odds ratio, 5.13; 95% CI, 1.44 to 20.64; P = .015); the ORR was 40% (30 of 75; 95% CI, 29% to 52%) and 17% (7 of 41; 95% CI, 7% to 32%), respectively, in patients with measurable and/or nonmeasurable CNS lesions (odds ratio, 3.24; 95% CI, 1.33 to 8.81; P = .014). Median CNS duration of response in patients with measurable and/or nonmeasurable CNS lesions was 8.9 months (95% CI, 4.3 months to not calculable) for osimertinib and 5.7 months (95% CI, 4.4 to 5.7 months) for platinum-pemetrexed; median CNS progression-free survival was 11.7 months and 5.6 months, respectively (hazard ratio, 0.32; 95% CI, 0.15 to 0.69; P = .004). Conclusion Osimertinib demonstrated superior CNS efficacy versus platinum-pemetrexed in T790M-positive advanced NSCLC.

Integrity signals

Registry

Crossref · 10.1200/jco.2018.77.9363

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379
Self-citation
Drug Transport across the Blood–Brain Barrier
Pardridge, W. M. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.126 · Cited by 1,994
Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial
Mulvenna, P., Nankivell, M. G., Barton, R., Finn, C. F., Wilson, P., McColl, E., MOORE, B. J., Brisbane, I., Ardron, D., Holt, T., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30825-x · Cited by 723
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity
Ballard, P., Yates, J. W. T., Yang, Z., Kim, D.-W., Yang, J. C.-H., Cantarini, M., Pickup, K., Jordan, A., Hickey, M., Grist, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0399 · Cited by 718
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
Goss, G. D., Tsai, C., Shepherd, F. A., Bazhenova, L. A., Lee, J. S., Chang, G., Crinò, L., Satouchi, M., Chu, Q. S.-C., Hida, T., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30508-3 · Cited by 654
Self-citation
Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component
Yang, J. C.-H., Ahn, M.-J., Kim, D.-W., Ramalingam, S. S., Sequist, L. V., Su, W.-C., Kim, S.-W., Kim, J.-H., Planchard, D., Felip, E., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.3223 · Cited by 571
Self-citation
Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers
Rangachari, D., Yamaguchi, N., VanderLaan, P. A., Folch, E. E., Mahadevan, A., Floyd, S., Uhlmann, E. J., Wong, E. T., Dahlberg, S. E., Huberman, M. S., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.01.020 · Cited by 547
Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer
Togashi, Y., Masago, K., Masuda, S., Mizuno, T., Fukudo, M., Ikemi, Y., Sakamori, Y., Nagai, H., Kim, Y. H., Katsura, T., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1929-4 · Cited by 282
Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)–Pretreated Non–Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease
Hoffknecht, P., Tufman, A., Wehler, T., Pelzer, T., Wiewrodt, R. G., Schütz, M., Serke, M. H., Stöhlmacher-Williams, J., Märten, A., Huber, R. M., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000380 · Cited by 259
CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials
Goss, G., Tsai, C.-M., Shepherd, F. A., Ahn, M.-J., Bazhenova, L., Crinò, L., de Marinis, F., Felip, E., Morabito, A., Hodge, R., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx820 · Cited by 247
Self-citation

Show all 18 references

Sorted by citations

Items 301–400 of 518

Real-World Analysis of the EGFR Mutation Test in Tissue and Plasma Samples from Non-Small Cell Lung Cancer
Lee, H., Han, J., & Choi, Y. (2021) · Diagnostics · doi:10.3390/diagnostics11091695 · Cited by 7
Self-citation
Brain metastases from non-small cell lung carcinoma: an overview of classical and novel treatment strategies
Martín, M., Hernánz, R., Vallejo, C., Guerrero, L., Mielgo-Rubio, X., Martín, A. L., Trujillo-Reyes, J. C., & Couñago, F. (2022) · Reports of Practical Oncology & Radiotherapy · doi:10.5603/rpor.a2022.0050 · Cited by 7
Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation: A pooled analysis of two clinical studies
Yang, S., Wu, S., Zhao, Y., Chen, G., Zhu, B., Li, X., Wang, K., Shi, J., Cang, S., Yao, W., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107194 · Cited by 7
A Review of Recent Advances in the Molecular Mechanisms Underlying Brain Metastasis in Lung Cancer
Guan, C., Zhang, X., & Yu, L. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0416 · Cited by 7
Real-Life Efficacy of Osimertinib in Pretreated Octogenarian Patients with T790M-Mutated Advanced Non-small Cell Lung Cancer
Auliac, J. B., Saboundji, K., Andre, M., Madelaine, J., Quéré, G., Masson, P., Vergnenégre, A., Lamy, R., Raymond, S., Chiappa, A.-M., et al. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00646-4 · Cited by 7
Primary CNS Metastatic BRAF-mutated Lung Adenocarcinoma With Complete Intracranial Response to BRAF/MEK Inhibition
Tsakonas, G., Grozman, V., & Ekman, S. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.05.006 · Cited by 7
Improving outcomes for brain metastases in EGFR mutated NSCLC
Carlisle, J. W., & Ramalingam, S. S. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.05.08 · Cited by 7
Upfront osimertinib in EGFR-mutated non-small cell lung cancer: is brain still a sanctuary?
Leonetti, A., Facchinetti, F., & Tiseo, M. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.11.69 · Cited by 7
Third-Generation EGFR Tyrosine Kinase Inhibitor for Central Nervous System Metastases EGFR-Mutant NSCLC: Current Evidence and Future Perspectives
Li, Z., & Lü, S. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.09.1440 · Cited by 7
Clinical Outcomes of Patients with Non-Small Cell Lung Cancer Leptomeningeal Disease Following Receipt of EGFR-Targeted Therapy, Immune-Checkpoint Blockade, Intrathecal Chemotherapy, or Radiation Therapy Alone
Mills, M. N., Uno, A., Li, P. X., Liveringhouse, C. L., Kim, Y., Oliver, D. E., Perez, B. A., Creelan, B., Yu, M. A., Forsyth, P. A., et al. (2024) · Clinical Lung Cancer · doi:10.1016/j.cllc.2024.04.005 · Cited by 6
Prevalence, therapeutic approaches, and survival rates of brain metastases in non-small cell lung cancer: a multi-institutional claims-based study from 2014 to 2024
Parker, M., Jiang, K., Kalluri, A. L., Arbuiso, A. G., Carmichael, A., Materi, J. D., Azad, T. D., Ha, J. S., Sahebjam, S., Kamson, D. O., et al. (2025) · Journal of Neuro-Oncology · doi:10.1007/s11060-025-05139-1 · Cited by 6
A meta-analysis of the comparing of the first-generation and next-generation TKIs in the treatment of NSCLC
Li, Y., Zhang, X., Chen, W., Lv, X., Yang, J., Xu, Y., & Zhang, M. (2019) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2019283 · Cited by 6
Emerging Biomarkers for Diagnosis, Prevention and Treatment of Brain Metastases—From Biology to Clinical Utility
Croft, P. K., Joshi, V., Saunus, J. M., & Lakhani, S. R. (2022) · Diseases · doi:10.3390/diseases10010011 · Cited by 6
Current pharmacologic treatment of brain metastasis in non-small cell lung cancer
Okuno, T., Isobe, T., & Tsubata, Y. (2024) · Clinical & Experimental Metastasis · doi:10.1007/s10585-024-10276-4 · Cited by 6
CNS Outcomes of Osimertinib Plus Chemotherapy in Patients With EGFR Mutation Positive Lung Cancer Beyond Osimertinib Progression
Wong, W. K. Y., Mok, K. K. S., Tsui, G., Chen, O. H., Loong, H. H.-F., Chan, L. L., Yan, K., Mo, F. K. F., Lee, K., Lam, K. C., et al. (2025) · Clinical Lung Cancer · doi:10.1016/j.cllc.2025.01.007 · Cited by 6
Self-citation
Ethyl acetate extract of Ruta graveolens: a specific and potent inhibitor against the drug-resistant EGFR_T790M mutant in NSCLC
Kumar, V., Chauhan, L., Singh, D., Kumar, A., Kulandaisamy, R., Kushwaha, T., Baswal, K., Singh, R., Kumar, S., Gholap, S. L., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1570108 · Cited by 6
Population Pharmacokinetics and Exposure‐Response Analysis of First‐Line Osimertinib Plus Chemotherapy in Patients with EGFR ‐Mutated Advanced NSCLC
Yang, J., Olabode, D., Sawant‐Basak, A., Baldry, R., Vishwanathan, K., Bachina, S., Todd, A., Ghiorghiu, D. C., Rukazenkov, Y., Zhou, D., et al. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3759 · Cited by 6
Self-citation
The efficacy and safety of Osimertinib in advanced non-small cell lung cancer patients with Thr790Met resistance mutations: a systematic review and meta-analysis
Cui, S., Zhang, Y., Liu, L., Li, Y., Zhou, R., Huang, X., Cao, S., Huo, X., & Wang, N. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-20-1357 · Cited by 6
Exceptional Response of a Large and Symptomatic EGFR-Mutant Brain Metastasis to Osimertinib: Case Report and Review of the Literature
Ozair, M. Z., Giantini-Larsen, A., Eng, J., & Moss, N. S. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00485 · Cited by 6
Predictors of Lung Adenocarcinoma With Leptomeningeal Metastases: A 2022 Target-Therapy Assisted molGPA Model for LM
Zhang, M., Tong, J., Ma, W., Luo, C., Liu, H., Jiang, Y., Qin, L., Wang, X., Yuan, L., Zhang, J., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.903851 · Cited by 6
[Consensus on Application of Third-generation EGFR-TKI in EGFR Mutated NSCLC (2022 Version)].
(2022) · PubMed · doi:10.3779/j.issn.1009-3419.2022.101.47 · Cited by 6
A Novel and Highly Selective Epidermal Growth Factor Receptor Inhibitor, SMUZ106, for the Treatment of Glioblastoma
Jiang, Y., Huang, C., Huang, Y., Long, L., Wu, G., Guo, F., Huang, C., Liu, S., Zhu, Z., Wu, S., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051501 · Cited by 6
Current and Emerging Treatment Options for Patients with Metastatic EGFR-Mutated Non-small Cell Lung Cancer After Progression on Osimertinib and Platinum-Based Chemotherapy: A Podcast Discussion
Patel, S. P., & Patel, J. D. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02680-1 · Cited by 6
Successful therapy using high-dose furmonertinib for non-small cell lung cancer with leptomeningeal metastasis: a case report and literature review
Chen, T., Chen, J., Liu, D., Shu, Y.-L., Fu, M.-Y., Gou, H., Lei, K., & Jia, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1233198 · Cited by 6
Comparative effectiveness of lazertinib in patients with EGFR T790M-positive non-small-cell lung cancer using a real-world external control
Jeon, H., Kwak, M., Kim, S., Yu, H.-Y., Shin, J., & Jung, H. A. (2024) · Scientific Reports · doi:10.1038/s41598-024-65220-z · Cited by 6
Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies
Ahn, M., Han, J., Kim, D., Cho, B. C., Kang, J. H., Kim, S.-W., Yang, J. C., Mitsudomi, T., & Lee, J. S. (2019) · Cancer Research and Treatment · doi:10.4143/crt.2019.200 · Cited by 6
Self-citation
A Phase II Study to Assess the Efficacy of Osimertinib in Patients With EGFR Mutation-positive NSCLC Who Developed Isolated CNS Progression (T790M-negative or Unknown) During First- or Second-generation EGFR-TKI or Systemic Disease Progression (T790M-negative) After Treatment With First- or Second-generation EGFR-TKI and Platinum-based Chemotherapy (WJOG12819L)
Takeda, M., Shimokawa, M., Nakamura, A., Nosaki, K., Watanabe, Y., Kato, T., Hayakawa, D., Tanaka, H., Takahashi, T., Kogure, Y., et al. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.12.009 · Cited by 6
Analyses of CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC from ASTRIS Korean Subset, Open-Label Real-World Study
Ahn, B., Kim, J. H., Pyo, K., Lim, S. M., Hong, M. H., Kim, H. R., & Cho, B. C. (2021) · Cancers · doi:10.3390/cancers13153681 · Cited by 6
Self-citation
Amivantamab: A Potent Novel EGFR/c-MET Bispecific Antibody Therapy for EGFR -mutated Non-small Cell Lung Cancer
Guo, M. Z., Marrone, K. A., Spira, A. I., Freeman, K., & Scott, S. C. (2021) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2021.17.1.42 · Cited by 7
Survival Benefit from Surgical Resection in Lung Cancer Patients with Brain Metastases: a Single-Center, Propensity-Matched Analysis Cohort Study
Wang, Z.-N., Jiang, X., Lü, J., Guo, X., He, Z., Duan, H., Liang, L., Cui, R., Hu, H., Zhang, X., et al. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-11365-y · Cited by 6
SEOM-GEINO clinical guideline of systemic therapy and management of brain central nervous system metastases (2021)
Martinez‐García, M., Servitja, S., Quintela, N. V., Fernández, A. A., Jaime, A. B., de Ibargüen, B. C. S., Barco, S. D., Campelo, R. G., Sarrió, R. G., & Sepúlveda-Sánchez, J. M. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02803-0 · Cited by 6
Strategies to prevent brain metastasis
Soffietti, R., Pellerino, A., & Rudà, R. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000572 · Cited by 6
Complete Remission of Multiple Brain Metastases in a Patient with EGFR-Mutated Non-Small-Cell Lung Cancer Treated with First-Line Osimertinib without Radiotherapy
Ameku, K., & Higa, M. (2020) · Case Reports in Oncological Medicine · doi:10.1155/2020/9076168 · Cited by 6
Clinical Outcomes of Surgical Resection for Brain Metastases from Non-small Cell Lung Cancer
NAKAO, T., Okuda, T., YOSHIOKA, H., & Fujita, M. (2020) · Anticancer Research · doi:10.21873/anticanres.14483 · Cited by 6
Epidermal growth factor receptor-targeted therapy for the treatment of non-small cell lung cancer: a review of phase II and III trials
Lu, H.-L., Jie, G., & Wu, Y.-L. L. C. (2022) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2022.2063836 · Cited by 8
Self-citation
Prognostic Analysis of Pathological Stage I Lung Adenocarcinoma Harboring Major EGFR Mutations
Takamori, S., Endo, M., Hamada, A., Ohara, S., Fukuda, S., Tomioka, Y., Takamori, S., Osoegawa, A., Nomura, K., Fujino, K., et al. (2024) · Clinical Lung Cancer · doi:10.1016/j.cllc.2024.12.011 · Cited by 5
A Review on EGFR-Tyrosine Kinase Inhibitors and their Resistance Mechanisms
Naim, M. J., & Samad, A. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128349342250121053445 · Cited by 5
The role of the neurologist in the diagnosis and treatment of brain metastases and carcinomatous meningitis
Pellerino, A., Garbossa, D., Rudà, R., & Soffietti, R. (2023) · Revue Neurologique · doi:10.1016/j.neurol.2023.03.005 · Cited by 5
Potential roles of tumor microenvironment in gefitinib-resistant non-small cell lung cancer: A narrative review
Mu-tong, C. H. E. N., Li, B., Zhang, E.-P., & Zheng, Q. L. (2023) · Medicine · doi:10.1097/md.0000000000035086 · Cited by 6
The Landscape and Management of Brain Parenchymal and Leptomeningeal Metastases in EGFR Mutated Non-Small Cell Lung Cancer
Hyak, J. M., & Rashdan, S. (2025) · Cancers · doi:10.3390/cancers17152434 · Cited by 5
Computed tomography‐based radiomics and clinical‐genetic features for brain metastasis prediction in patients with stage III / IV epidermal growth factor receptor‐mutant non‐small‐cell lung cancer
Zheng, M., Sun, X., Qi, H., Zhang, M., & Xing, L. (2024) · Thoracic Cancer · doi:10.1111/1759-7714.15410 · Cited by 5
EGFR testing practices, treatment choice and clinical outcomes in advanced NSCLC in a real-world setting: A retrospective analysis of a US-based electronic health records database
Subramanian, J., Gregg, J. P., Berktaş, M., Li, J., & Leighl, N. B. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108412 · Cited by 5
Analysis of the clinical effect of osimertinib on 90 cases with advanced lung adenocarcinoma
Gao, Z., Wang, W., Gu, A., Lu, J., Huang, A., Xiong, L., Han, B., Jiang, L., & Shi, C. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-685 · Cited by 5
Updates on Molecular Targeted Therapies for Intraparenchymal CNS Metastases
Sharma, A., Singer, L., & Kumthekar, P. (2021) · Cancers · doi:10.3390/cancers14010017 · Cited by 6
Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) in EGFR-Mutated Lung Adenocarcinoma: A Real-World Study in Chinese Patients
Xu, Z., Hao, X., Wang, Q., Wang, J., Yang, K., Wang, S., Teng, F., Li, J., & Xing, P. (2022) · Cancer Management and Research · doi:10.2147/cmar.s346173 · Cited by 5
[Research Progress in the Treatment of Brain Metastases from Non-small Cell Lung Cancer].
Han, X., & Li, H. (2020) · PubMed Central · doi:10.3779/j.issn.1009-3419.2020.102.39 · Cited by 5
Adjuvant therapies in stages I–III epidermal growth factor receptor-mutated lung cancer: current and future perspectives
Kris, M. G., Mitsudomi, T., & Peters, S. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-723 · Cited by 5
Impact of clinical features of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients on osimertinib efficacy
Lazzari, C., Gregorc, V., & Santarpía, M. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.10.67 · Cited by 5
Targeting PLK1 potentiates the antitumor efficacy of EGFR-TKIs through inhibiting the JAK1/STAT3 pathway
Li, C., Shi, S., Li, L., Wang, Y., Yao, M., Yu, C., Yu, C., & Xie, C. (2026) · Cell Death and Disease · doi:10.1038/s41419-025-08220-9 · Cited by 4
Tyrosine Kinase Inhibitors as a Treatment of Symptomatic CNS Metastases in Oncogene-Driven NSCLC
Gal, O., Dudnik, E., Rotem, O., Finkel, I., Peretz, I., Zer, A., Mandel, J. J., Benouaich‐Amiel, A., Siegal, T., Bar, J., et al. (2020) · Journal of Oncology · doi:10.1155/2020/1980891 · Cited by 4
Prognostic value of MRI volumetric parameters in non-small cell lung cancer patients after immune checkpoint inhibitor therapy: comparison with response assessment criteria
Roh, Y. H., Park, J. E., Kang, S., Yoon, S., Kim, S., & Kim, H. S. (2023) · Cancer Imaging · doi:10.1186/s40644-023-00624-0 · Cited by 4
Self-citation
EML4-ALK Variant 3a/b as a mechanism of osimertinib resistance in a patient with EGFR L858R positive NSCLC
Yamaguchi, T., Masago, K., Sasaki, E., Kuroda, H., Matsushita, H., & Horio, Y. (2023) · Cancer Genetics · doi:10.1016/j.cancergen.2023.12.001 · Cited by 4
Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non-small cell lung cancer
Chang, G., Shih, J., Yu, C., Chao, H., Yang, C., Lin, C., Hung, J., Hsiao, S., Wang, C.-C., Chian, C., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0303046 · Cited by 4
EGFR mutation testing, treatment and survival in stage I–III non-small cell lung cancer: CancerLinQ Discovery database retrospective analysis
Muthusamy, B., Berktaş, M., Li, J., Thomas, D. S., Sun, P., Taylor, A., & Pennell, N. A. (2024) · Future Oncology · doi:10.1080/14796694.2024.2347826 · Cited by 4
Observational study of the efficacy and safety of first-line osimertinib and later treatments for uncommon epidermal growth factor receptor-activating mutation-positive advanced non-small cell lung cancer
Hirata, T., Watanabe, K., Hosomi, Y., Yoh, K., Usui, K., Kishi, K., Naka, G., Tamano, S., Uemura, K., & Kunitoh, H. (2024) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyae176 · Cited by 4
Analysis of prognostic factors and risk prediction in brain metastases: a SEER population-based study
Ji, Q., Yang, Z., Kang, X., Zhou, L., Chen, F., & Li, W. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1523069 · Cited by 4
Successful osimertinib treatment in a patient who exhibited intramedullary spinal cord metastases of lung adenocarcinoma with an acquired EGFR T790M mutation
Horiuchi, K., Asakura, T., Sakaguchi, S., & Saito, F. (2019) · BMJ Case Reports · doi:10.1136/bcr-2019-229310 · Cited by 4
[Acquired Drug Resistance Mechanism of Osimertinib in the Targeted Therapy of Non-small Cell Lung Cancer].
Zhao, Z., Ni, Y., Li, L., & Xin, T. (2020) · PubMed Central · doi:10.3779/j.issn.1009-3419.2020.103.02 · Cited by 4
Improved survival in patients with unresectable stage III EGFR ‐mutant adenocarcinoma with upfront EGFR ‐tyrosine kinase inhibitors
Wang, S., Lai, C., Chen, C., Yang, S., Chang, C., Lin, C.-Y. J., Yen, Y., Tseng, Y., Su, P., Lin, C., et al. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.14237 · Cited by 4
[Research Progress of Proteolysis Targeting Chimeria in NSCLC Therapy].
Jiang, L., Zhang, J., Hu, J., Qi, H., & Xu, H. Y. (2022) · PubMed Central · doi:10.3779/j.issn.1009-3419.2022.102.19 · Cited by 4
Upfront Use of First-/Second-Generation EGFR-TKI Followed by Osimertinib Shows Better Prognosis than Upfront Osimertinib Therapy in Japanese Patients with Non-small-cell Lung Cancer with Exon 19 Deletion: A Single-Center Retrospective Study
Hori, T., Yamamoto, K., Ito, T., Ikushima, S., Omura, T., & Yano, I. (2023) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b22-00794 · Cited by 4
Separation, Identification, Isolation and Characterization of Degradation Product of Osimertinib Tablets by UPLC-QTOF-MS/MS and NMR: Evaluation of In-Silico Safety Assessment for Osimertinib (OSM) and Degradation Product (DP)
Bhutnar, A. D., Saple, S. R., & Vaidya, V. V. (2021) · Advances in Biological Chemistry · doi:10.4236/abc.2021.111003 · Cited by 4
Immunotherapeutic and Targeted Strategies for Managing Brain Metastases from Common Cancer Origins: A State-of-the-Art Review
Podder, V., Bellur, S. S., Margolin, K. A., Advani, P. P., Mahtani, R. L., Subbiah, V., Novo, G. B., Ranjan, T., & Ahluwalia, M. S. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01593-8 · Cited by 4
Pattern of brain metastases and survival in lung adenocarcinoma with KRAS or EFGR mutation
Faehling, M., Fallscheer, S., Schmiederer, J., Sträter, J., Christopoulos, P., Lengerke, C., & Seifarth, H. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108803 · Cited by 3
Durvalumab plus etoposide–platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD
Okamoto, I., Cho, B. C., Goldberg, S. B., Goldman, J. W., de Langen, A. J., Piotrowska, Z., Riess, J. W., Yu, H. A., Campelo, M. R. G., Cetnar, J. P., et al. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2026.109501 · Cited by 3
Improvements in the Synthesis of the Third‐Generation EGFR Inhibitor Osimertinib
Voulgari, P., Alivertis, D., & Skobridis, K. (2021) · Helvetica Chimica Acta · doi:10.1002/hlca.202100066 · Cited by 3
Alternating Administration of Osimertinib for Leptomeningitis and Docetaxel Plus Ramucirumab for Lung Adenocarcinoma Resistant to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Tomizawa, H., Mouri, A., Mikoshiba, S., Tsukamoto, K., Abe, Y., Oda, M., Tsuchiya, M., Yamana, T., Suhara, K., & Kamimura, M. (2024) · Internal Medicine · doi:10.2169/internalmedicine.4427-24 · Cited by 3
ARID1A mutational status in non-small cell lung cancer: from molecular pathology to clinical implications with a focus on the relationships with EGFR
Lecce, C. D., Eccher, S., Simbolo, M., Cocomazzi, A., Piredda, M. L., Caliò, A., Cima, L., Munari, E., Veronese, N., Avancini, A., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108594 · Cited by 3
Clinical significance of bifocal treatment for synchronous brain metastasis in T1-2 non-small-cell lung cancers: JNETS0301
Suzuki, K., Shiono, S., Hasumi, T., Sakurada, A., Minowa, M., Sato, N., Uramoto, H., Deguchi, H., Suzuki, J., & Okada, Y. (2021) · General Thoracic and Cardiovascular Surgery · doi:10.1007/s11748-020-01568-z · Cited by 3
State of affairs regarding targeted pharmacological therapy of cancers metastasized to the brain
Steiger, H., Vollmer, K., Rogers, S. J., & Schwyzer, L. (2022) · Neurosurgical Review · doi:10.1007/s10143-022-01839-8 · Cited by 3
Building Team Medicine in the Management of CNS Metastases
Baskaran, A. B., Buerki, R. A., Khan, O. H., Gondi, V., Stupp, R., Lukas, R. V., & Villaflor, V. M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12123901 · Cited by 3
Optimal sequence of LT for symptomatic BM in EGFR-mutant NSCLC: a comparative study of first-line EGFR-TKIs with/without upfront LT
Niu, L., Wu, H., Gao, R., Chen, L., Wang, J., Duan, H., Long, Y., Xie, Y., Zhou, Q., & Zhou, R. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05538-9 · Cited by 3
Enhancing intracranial efficacy prediction of osimertinib in non-small cell lung cancer: a novel approach through brain MRI radiomics
Tang, X., Li, Y., Qian, W., Han, P., Yan, W., & Yang, Z. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1399983 · Cited by 3
Brain metastases in Japanese NSCLC patients: prognostic assessment and the use of osimertinib and immune checkpoint inhibitors—retrospective study
Higaki, H., Nishioka, K., Otsuka, M., Nishikawa, N., Shido, M., Minatogawa, H., Nishikawa, Y., Takashina, R., Hashimoto, T., Katoh, N., et al. (2023) · Radiation Oncology · doi:10.1186/s13014-023-02218-3 · Cited by 3
Effect of Different Timing of Local Brain Radiotherapy on Survival of EGFR-Mutated NSCLC Patients with Limited Brain Metastases
Wang, Y., Wu, S., Li, J., Liang, X., & Zhou, X. (2023) · Brain Sciences · doi:10.3390/brainsci13091280 · Cited by 3
Impact of Disease and Treatment Response in Drug–Drug Interaction Studies: Osimertinib and Simvastatin in Advanced Non‐Small Cell Lung Cancer
Vishwanathan, K., Cantarini, M., So, K., Masson, E., Fetterolf, J., Ramalingam, S. S., & Harvey, R. D. (2019) · Clinical and Translational Science · doi:10.1111/cts.12688 · Cited by 3
Treatment Strategies for Brain Metastases in the Era of Molecular Targeted Therapy
Iuchi, T., Shingyoji, M., & Hara, R. (2019) · Japanese Journal of Neurosurgery · doi:10.7887/jcns.28.715 · Cited by 3
Improving the Management of Brain Metastases in Oncogene-Addicted Non–Small-Cell Lung Cancer
Fung, A. S., & Leighl, N. B. (2019) · Journal of Oncology Practice · doi:10.1200/jop.19.00575 · Cited by 3
New data highlighting the efficacy and safety outcomes of third‐generation EGFR‐TKI in NSCLC patients with rare EGFR mutations
Zhang, W., Li, F., & Gao, W. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13334 · Cited by 3
Refining Lung Cancer Brain Metastasis Models for Spatiotemporal Dynamic Research and Personalized Therapy
Chen, Y., Zhang, A., Wang, J.-R., Pan, H., Liu, L., & Li, R. (2025) · Cancers · doi:10.3390/cancers17091588 · Cited by 2
High-dose furmonertinib plus bevacizumab in EGFR-mutant non-small cell lung cancer with brain metastases after resistance to third-generation EGFR-TKIs: A retrospective study
Pan, Y., Li, M., Yu, M., Chen, J., Yu, H., Liu, K., & Chen, L. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102500 · Cited by 2
Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real–world study
Ahn, M., Lin, S. H., Yang, C., Lee, J. B., Neal, J. W., Okishio, K., Nishino, K., Smith, D., Rauter, M., Jimenez, M. I., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108748 · Cited by 2
Self-citation
Cerebrospinal fluid ctDNA clarifies clonal divergence: leptomeningeal flare of EGFR-mutant disease after switch to selpercatinib for acquired RET fusion
Kunimasa, K., Tamiya, M., Inoue, T., Mamesaya, N., Tanaka, T., Komuta, K., Futamura, S., Honma, K., & Nishino, K. (2025) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2025.100450 · Cited by 2
Update on the management of leptomeningeal disease in solid organ malignancy: Systemic, intrathecal and novel therapies
Fisher, S., Topp, M. D., Airth, A., Campbell, B., Stylli, S. S., Hovens, C. M., & Dimou, J. (2026) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2026.112076 · Cited by 2
Recent advances in synthetic strategies of fourth-generation EGFR tyrosine kinase inhibitors under clinical trials for the treatment of resistant non-small cell lung cancer (NSCLC)
Kadam, V., & Patel, H. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110353 · Cited by 2
Can Quantitative Measures of T790M Allelic Fraction Predict Survival Outcomes in Patients Receiving Osimertinib? Observations From an Early Access Programme
Chan, O. S. H., Lee, V. H.-F., Nyaw, S. F., Kam, T. Y., Lee, K., & Lam, K. C. (2021) · Clinical Oncology · doi:10.1016/j.clon.2021.01.011 · Cited by 2
Epidermal growth factor receptor-Mutated Non-small-cell Lung Cancer with Intracranial Progressions and Stable Extracranial Diseases Benefit from Osimertinib Regardless of T790M Mutational Status
Liao, J., Huang, Y., Gan, J., Pang, L., Ali, W. A. S., Yang, Y., Chen, L., Zhang, L., & Fang, W. (2022) · Cancer Control · doi:10.1177/10732748221081360 · Cited by 2
Pulmonary effects of cancer treatments
Karampitsakos, Τ., Sampsonas, F., Spagnolo, P., & Τzouvelekis, Α. (2022) · European Respiratory Society eBooks · doi:10.1183/2312508x.10020421 · Cited by 2
Clinical efficacy and prognosis analysis of treatment regimens for EGFR mutant non-small cell lung cancer and brain metastasis: a retrospective study
Wang, H., Xing, R., Li, M., Zhang, M., Wei, C., Zhang, G., Niu, Y., Ma, Z., & Yan, X. (2023) · BMC Cancer · doi:10.1186/s12885-023-10744-2 · Cited by 2
An association of epidermal growth factor receptor mutation subtypes with prognostic prediction and site-specific recurrence in advanced stage lung cancer patients
Joshi, J. S., Pandit, A., Tarapara, B. V., Patel, H. V., Bhavnagari, H. M., Panchal, H. P., & Shah, F. D. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08432-2 · Cited by 2
Prioritizing Radiation and Targeted Systemic Therapies in Patients with Resected Brain Metastases from Lung Cancer Primaries with Targetable Mutations: A Report from a Multi-Site Single Institution
Wuu, Y. R., Kokabee, M., Gui, B., Lee, S., Stone, J., Karten, J., D’Amico, R. S., Vojnic, M., & Wernicke, A. G. (2024) · Cancers · doi:10.3390/cancers16193270 · Cited by 2
Clinical and Radiographic Benefit of a Patient With Metastatic Non-Small Cell Lung Cancer Harboring an EGFR::ERBB4 Fusion Through Use of EGFR Tyrosine Kinase Inhibitors
Guimarães-Young, A., Davies, K. D., Trevisan, P., Nijmeh, H., Haag, M. M., Aisner, D. L., & Patil, T. (2024) · JCO Precision Oncology · doi:10.1200/po-24-00526 · Cited by 2
Osimertinib as Salvage Therapy in Advanced Non‐Small Cell Lung Cancer After Aumolertinib Resistance With T790M Mutation: A Case Report
Tang, Y., Xu, J., Chen, Q., Lu, J., Ren, L., Lan, T., Liao, T., Chen, X., Hui, Y., Zhang, J., et al. (2025) · Clinical Case Reports · doi:10.1002/ccr3.70219 · Cited by 2
Efficacy and Safety of EGFR-TKI Combined With Early Brain Radiotherapy Versus TKI Alone in Patients With EGFR-Mutated NSCLC With Brain Metastases: A Systematic Review and Meta-Analysis
Zeng, Z., Feng, S., Gao, T., Chen, C., Chen, J., Chen, J., & Lian, Y. (2025) · Clinical Lung Cancer · doi:10.1016/j.cllc.2025.04.010 · Cited by 2
A Phase 2 Single-Arm Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis NSCLC: Results for the First-Line Cohort of the OCEAN Study (LOGIK 1603/WJOG 9116L)
Wakuda, K., Yamaguchi, H., Kenmotsu, H., Fukuda, M., Ito, K., Tsuchiya‐Kawano, Y., Tanaka, K., Harada, T., Nakatani, Y., Miura, S., et al. (2023) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2023.100587 · Cited by 2
Strategien zur Überwindung der erworbenen EGFR-TKI-Resistenz durch T790M spezifische Substanzen am Beispiel von Osimertinib
Griesinger, F., Radke, S., Lüers, A., Deschler-Baier, B., Kimmich, M., Sebastian, M., Schulz, C. K. J., Brugger, W., Wiewrodt, R. G., Pirker, R., et al. (2018) · Pneumologie · doi:10.1055/a-0647-9835 · Cited by 2
Response of Leptomeningeal Metastases in EGFR-Mutated Non-Small-Cell Lung Cancer to Afatinib in the Absence of Radiotherapy
Quintero, N. E. L., González-Hoyos, D., Yepes, A., Herrera, D. A., Peláez, S., Caicedo-Zamudio, C., Blanco-Daza, E., & López, J. C. (2019) · Case Reports in Oncological Medicine · doi:10.1155/2019/1939703 · Cited by 2
Does an optimal management of brain metastases from oncogenic-driver non–small cell lung cancer exist?
Rudà, R., & Soffietti, R. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz238 · Cited by 2
Durable Response of Leptomeningeal Disease With Osimertinib and Pemetrexed in EGFR-Mutated Metastatic NSCLC: A Case Report
Merkhofer, C. M., & Baik, C. S. (2021) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2021.100177 · Cited by 2
A Phase II study of nab-Paclitaxel (nab-P) in patients with advanced non-small cell lung cancer with EGFR mutations after frontline tyrosine kinase inhibitor therapy
Baik, C. S., Lee, S. Y., Cook, K., Wallace, S. G., Wood, R. L., Santana-Dávila, R., Chow, L. Q. M., Rodriguez, C. P., Eaton, K. D., & Martins, R. G. (2021) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2021.100416 · Cited by 2

Authors: Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Han, J.-Y., Katakami, N., Kim, H. R., Hodge, R., Kaur, P., Brown, A. P., Ghiorghiu, D., Papadimitrakopoulou, V. A., & Mok, T. S. K.
Affiliations: Yonsei University (KR)
ORCID: Wu, Yi-Long
Ahn, Myung-Ju
Garassino, Marina Chiara
Han, Ji-Youn
Katakami, Nobuyuki
Kim, Hye Ryun
Hodge, Rachel
Papadimitrakopoulou, Vassiliki A.
Mok, Tony S.K.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2018-09-10
Volume: 36
Issue: 26
Pages: 2702-2709
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2018.77.9363
OpenAlex: W2887416920
Cited by: 517
References: 18
Citations by year: 2026: 30 · 2025: 59 · 2024: 63 · 2023: 79 · 2022: 66 · 2021: 75 · 2020: 70 · 2019: 62 · 2018: 13
FWCI: 41.63
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › Brain Metastases and Treatment
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: osimertinib, T790M mutation, advanced non-small cell lung cancer, central nervous system metastasis, EGFR tyrosine kinase inhibitors, CNS penetration, AURA3 trial, subgroup analysis
MeSH terms: Pemetrexed, Acrylamides, Adult, Aged, Aged, 80 and over, Aniline Compounds, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Cisplatin, Female, Humans, Indoles, Lung Neoplasms, Male, Middle Aged, Mutation, Pyrimidines, Carboplatin, Protein Kinase Inhibitors, Young Adult, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks